Innovations in the systemic treatment of medullary thyroid cancer with kinase inhibitors
DOI:
https://doi.org/10.12775/JEHS.2023.50.01.004Keywords
Medullary thyroid cancer, multiple endocrine neoplasia type 2, RETAbstract
Introduction: Medullary thyroid carcinoma is a primary thyroid neoplasm originating from thyroid C cells. It can be familial or sporadic. The familial form is associated with multiple endocrine neoplasia (MEN) syndrome types 2A and 2B and is caused by a mutation in the RET gene, which encodes a tyrosine kinase receptor. Treatment of medullary thyroid cancer is mainly based on surgical resection of the thyroid gland, usually a total thyroidectomy. It can be followed-up by a chemotherapy, which has limited efficacy. Hence, there is a growing interest in new molecular therapies, such as tyrosine kinase inhibitors, which include vandetanib, cabozantinib, selpercatinib, pralsetinib, sorafenib and lenvatinib.
Objective: The review and presentation of the current state of knowledge on the systemic treatment of medullary thyroid cancer with kinase inhibitors.
Material and methods: Literature review based on available sources from PubMed database and Google Scholar.
Conclusions: Though systemic treatment options for medullary thyroid cancer continue to improve, patients with advanced neoplasms still have limited therapeutic options. Hence, further development of targeted treatment with kinase inhibitors, particularly those selective for the RET receptor is crucial. Molecular studies of mutations and signaling pathways involved in the oncopathogenesis of medullary thyroid cancer could contribute to the discovery of new therapeutic mechanisms, and drugs that target them, could potentially further improve disease progression-free survival (PFS) and overall survival (OS).
References
A. Miranda-Filho et al., “Thyroid cancer incidence trends by histology in 25 countries: a population-based study,” Lancet Diabetes Endocrinol, vol. 9, no. 4, pp. 225–234, Apr. 2021, doi: 10.1016/S2213-8587(21)00027-9.
D. Viola and R. Elisei, “Management of Medullary Thyroid Cancer,” Endocrinol Metab Clin North Am, vol. 48, no. 1, pp. 285–301, Mar. 2019, doi: 10.1016/J.ECL.2018.11.006.
B. Xu et al., “International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma,” J Clin Oncol, vol. 40, no. 1, pp. 96–103, Jan. 2022, doi: 10.1200/JCO.21.01329.
M. Kim and B. H. Kim, “Current Guidelines for Management of Medullary Thyroid Carcinoma,” Endocrinol Metab (Seoul), vol. 36, no. 3, pp. 514–524, Jun. 2021, doi: 10.3803/ENM.2021.1082.
N. H. Esfandiari and M. Papaleontiou, “Biochemical Testing in Thyroid Disorders,” Endocrinol Metab Clin North Am, vol. 46, no. 3, pp. 631–648, Sep. 2017, doi: 10.1016/J.ECL.2017.04.002.
S. A. Wells et al., “Revised American thyroid association guidelines for the management of medullary thyroid carcinoma,” Thyroid, vol. 25, no. 6, pp. 567–610, Jun. 2015, doi: 10.1089/THY.2014.0335/ASSET/IMAGES/LARGE/FIGURE3.JPEG.
J. Hadoux, F. Pacini, R. M. Tuttle, and M. Schlumberger, “Management of advanced medullary thyroid cancer,” Lancet Diabetes Endocrinol, vol. 4, no. 1, pp. 64–71, Jan. 2016, doi: 10.1016/S2213-8587(15)00337-X.
C. Romei, R. Ciampi, and R. Elisei, “A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma,” Nat Rev Endocrinol, vol. 12, no. 4, pp. 192–202, Apr. 2016, doi: 10.1038/NRENDO.2016.11.
R. I. Haddad et al., “Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network, vol. 20, no. 8, pp. 925–951, Aug. 2022, doi: 10.6004/JNCCN.2022.0040.
J. S. Mathiesen et al., “Multiple endocrine neoplasia type 2: A review,” Semin Cancer Biol, vol. 79, pp. 163–179, Feb. 2022, doi: 10.1016/J.SEMCANCER.2021.03.035.
M. Takahashi, J. Ritz, and G. M. Cooper, “Activation of a novel human transforming gene, ret, by DNA rearrangement,” Cell, vol. 42, no. 2, pp. 581–588, 1985, doi: 10.1016/0092-8674(85)90115-1.
V. Larouche, A. Akirov, C. M. Thomas, M. K. Krzyzanowska, and S. Ezzat, “A primer on the genetics of medullary thyroid cancer,” Curr Oncol, vol. 26, no. 6, pp. 389–394, 2019, doi: 10.3747/CO.26.5553.
M. B. Lodish and C. A. Stratakis, “RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer,” Expert Rev Anticancer Ther, vol. 8, no. 4, pp. 625–632, Apr. 2008, doi: 10.1586/14737140.8.4.625.
M. A, S. U, H. HJ, and D. H, “Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level,” J Clin Endocrinol Metab, vol. 90, no. 4, 2005, doi: 10.1210/JC.2004-1836.
S. A. Wells et al., “Revised American thyroid association guidelines for the management of medullary thyroid carcinoma,” Thyroid, vol. 25, no. 6, pp. 567–610, Jun. 2015, doi: 10.1089/THY.2014.0335/ASSET/IMAGES/LARGE/FIGURE3.JPEG.
D. Viola and R. Elisei, “Management of Medullary Thyroid Cancer,” Endocrinol Metab Clin North Am, vol. 48, no. 1, pp. 285–301, Mar. 2019, doi: 10.1016/j.ecl.2018.11.006.
R. M. Tuttle et al., “Thyroid carcinoma, version 2.2014,” J Natl Compr Canc Netw, vol. 12, no. 12, pp. 1671–1680, Dec. 2014, doi: 10.6004/JNCCN.2014.0169.
M. E. Cabanillas and M. A. Habra, “Lenvatinib: Role in thyroid cancer and other solid tumors,” Cancer Treat Rev, vol. 42, pp. 47–55, Jan. 2016, doi: 10.1016/J.CTRV.2015.11.003.
S. A. Wells et al., “Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial,” J Clin Oncol, vol. 30, no. 2, pp. 134–141, Jan. 2012, doi: 10.1200/JCO.2011.35.5040.
L. Koch, “Vandetanib—a new therapeutic option in advanced medullary thyroid cancer,” Nat Rev Endocrinol, vol. 8, no. 1, pp. 1–1, Jan. 2012, doi: 10.1038/nrendo.2011.198.
R. Elisei et al., “Cabozantinib in progressive medullary thyroid cancer,” J Clin Oncol, vol. 31, no. 29, pp. 3639–3646, Oct. 2013, doi: 10.1200/JCO.2012.48.4659.
S. I. Sherman et al., “Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study.,” https://doi.org/10.1200/jco.2013.31.15_suppl.6000, vol. 31, no. 15_suppl, pp. 6000–6000, May 2013, doi: 10.1200/JCO.2013.31.15_SUPPL.6000.
J. Capdevila et al., “A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer,” Thyroid, vol. 32, no. 5, p. 515, May 2022, doi: 10.1089/THY.2022.0027.
E. T. Lam et al., “Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer,” J Clin Oncol, vol. 28, no. 14, pp. 2323–2330, May 2010, doi: 10.1200/JCO.2009.25.0068.
H. G. Vuong et al., “Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis,” Head Neck, vol. 41, no. 8, pp. 2823–2829, Aug. 2019, doi: 10.1002/HED.25832.
M. Schlumberger et al., “Lenvatinib versus placebo in radioiodine-refractory thyroid cancer,” N Engl J Med, vol. 372, no. 7, pp. 621–630, Feb. 2015, doi: 10.1056/NEJMOA1406470.
L. Wirth et al., “Registrational results of LOXO-292 in patients with RET-altered thyroid cancers,” Annals of Oncology, vol. 30, p. v933, Oct. 2019, doi: 10.1093/ANNONC/MDZ394.093.
V. Subbiah et al., “Precision targeted therapy with BLU-667 for RET-driven cancers,” Cancer Discov, vol. 8, no. 7, pp. 836–849, Jul. 2018, doi: 10.1158/2159-8290.CD-18-0338/42851/AM/PRECISION-TARGETED-THERAPY-WITH-BLU-667-FOR-RET.
L. Højer Wang, M. Wehland, P. M. Wise, M. Infanger, D. Grimm, and M. C. Kreissl, “Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect,” International Journal of Molecular Sciences 2023, Vol. 24, Page 2312, vol. 24, no. 3, p. 2312, Jan. 2023, doi: 10.3390/IJMS24032312.
V. Subbiah et al., “Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study,” Lancet Diabetes Endocrinol, vol. 9, no. 8, pp. 491–501, Aug. 2021, doi: 10.1016/S2213-8587(21)00120-0.
V. Subbiah et al., “Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.,” https://doi.org/10.1200/JCO.2020.38.15_suppl.109, vol. 38, no. 15_suppl, pp. 109–109, May 2020, doi: 10.1200/JCO.2020.38.15_SUPPL.109.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Wiktoria Lipczyńska, Adam Jasiura, Hubert Kasprzak, Agata Justyńska, Hanna Krafzik, Konrad Warchoł, Przemysław Stępień, Sylwiusz Niedobylski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 309
Number of citations: 0